Next-generation vaccines that utilize T cells could potentially overcome the limitations of
current influenza vaccines that rely on antibodies to provide narrow subtype-specific …

Vaccination remains our main defence against influenza, which causes substantial annual
mortality and poses a serious pandemic threat. Influenza virus evades immunity by rapidly …

Highlights•Conserved viral targets have been identified that induce cross-reactive antibody
and T cell responses.•Cross-reactive antibodies and T cells contribute to broadly protective …

Influenza A is an important cause of morbidity and mortality worldwide. In the United States
alone influenza kills 30,000 to 50,000 people in a non-epidemic year and significantly more …

Current flu vaccines rely on the induction of strain-specific neutralizing antibodies, which
leaves the population vulnerable to drifted seasonal or newly emerged pandemic strains …

Introduction: The licensed seasonal influenza vaccines predominantly induce neutralizing
antibodies against immunodominant hypervariable epitopes of viral surface proteins, with …

Annual influenza vaccination is an effective way to prevent human influenza. Current
vaccines are mainly focused on eliciting a strain-matched humoral immune response …

Influenza is a major global health problem, causing infections of the respiratory tract, often
leading to acute pneumonia, life-threatening complications and even deaths. Over the last …

Influenza A virus is a respiratory pathogen which causes both seasonal epidemics and
occasional pandemics; infection continues to be a significant cause of mortality worldwide …

Highlights•Influenza infection is prevented by protective antibodies.•Flu-specific T cells can
reduce viral load and disease severity.•Stem region of HA and flu internal proteins (NP and …